Last reviewed · How we verify
fentanyl transmucosal
At a glance
| Generic name | fentanyl transmucosal |
|---|---|
| Also known as | Pecfent |
| Sponsor | Centre Henri Becquerel |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Pain Management With Pecfent in the Prevention of Pain Induced by Position in Radiotherapy (PHASE3)
- Intranasal Fentanyl in Treatment of Labour Pain (PHASE4)
- Sublingual Versus Endovenous Fentanyl for the Prehospital Analgesia in Patients With Limb Trauma on the Slope (PHASE4)
- Sublingual Versus Endovenous Fentanyl for Pain Treatment in Trauma Patients in the Emergency Room (PHASE4)
- Procedural Pain Treatment With Transmucosal Sublingual Fentanyl Tablet in Colonoscopy Patients (PHASE4)
- Analgesic Efficacy of Transmucosal Fentanyl for Breakthrough Pain Caused by Interventional Gastrostomy (PHASE4)
- Safety of Intranasal Fentanyl (PecFent®) in the Treatment of Procedural Pain in the Elderly (PHASE2, PHASE3)
- Bioequivalence of a Test Troche Formulation of Fentanyl Citrate (400 mcg) Compared to Actiq® 400 mcg, Cephalon, Inc. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- fentanyl transmucosal CI brief — competitive landscape report
- fentanyl transmucosal updates RSS · CI watch RSS
- Centre Henri Becquerel portfolio CI